Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Receives Consensus Recommendation of "Hold" from Analysts

Key Points

• Analysts have a consensus “Hold” rating on Inovio Pharmaceuticals, with four buys, two holds and one sell among seven analysts. The average 12-month price target is $3.25.
• INO shares opened at $0.77, below their 50-day and 200-day moving averages of $1.03 and $1.31, respectively, with a 52-week range of $0.56 to $2.98.
• Inovio reported a quarterly loss of $0.07 per share, beating the $0.22 loss expected by analysts; institutional investors own approximately 26.79% of the company.

Inovio Pharmaceuticals, Inc. (NASDAQ:INO - Get Free Report) has been given a consensus recommendation of "Hold" by the seven analysts that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $3.25.

Several equities analysts have commented on INO shares. Piper Sandler reiterated an "overweight" rating and issued a $4.00 target price on shares of Inovio Pharmaceuticals in a research report on Monday, August 3rd. HC Wainwright decreased their price objective on shares of Inovio Pharmaceuticals from $3.00 to $2.50 and set a "neutral" rating for the company in a research report on Monday, June 1st. Weiss Ratings raised shares of Inovio Pharmaceuticals from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Wednesday, July 29th. Finally, Wall Street Zen cut shares of Inovio Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Sunday, June 21st.

Institutional Investors Weigh In On Inovio Pharmaceuticals

Large investors have recently added to or reduced their stakes in the business. AQR Capital Management LLC acquired a new position in Inovio Pharmaceuticals in the first quarter valued at approximately $120,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Inovio Pharmaceuticals by 39.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,781 shares of the biopharmaceutical company's stock worth $34,000 after buying an additional 5,894 shares during the period. Qube Research & Technologies Ltd acquired a new stake in shares of Inovio Pharmaceuticals during the 2nd quarter worth approximately $234,000. Jane Street Group LLC grew its position in shares of Inovio Pharmaceuticals by 221.2% during the 2nd quarter. Jane Street Group LLC now owns 39,683 shares of the biopharmaceutical company's stock worth $81,000 after buying an additional 27,329 shares during the period. Finally, JPMorgan Chase & Co. increased its stake in shares of Inovio Pharmaceuticals by 1,667.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 65,206 shares of the biopharmaceutical company's stock valued at $153,000 after acquiring an additional 61,516 shares in the last quarter. Institutional investors and hedge funds own 26.79% of the company's stock.

Inovio Pharmaceuticals Trading Up 0.5%

Shares of Inovio Pharmaceuticals stock opened at $0.77 on Thursday. The firm's 50 day moving average is $1.03 and its 200 day moving average is $1.31. The firm has a market capitalization of $63.35 million, a PE ratio of -0.53 and a beta of 1.52. Inovio Pharmaceuticals has a 1 year low of $0.56 and a 1 year high of $2.98.

Inovio Pharmaceuticals (NASDAQ:INO - Get Free Report) last issued its quarterly earnings data on Wednesday, August 12th. The biopharmaceutical company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.15. As a group, research analysts anticipate that Inovio Pharmaceuticals will post -0.99 earnings per share for the current year.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio's business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.

Central to Inovio's platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source